Scilex Holding Company(SCLX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:00 PM ET (Korea 11/6 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -49.8 | Insider Own | 11.67% | Shs Outstand | 7.0M | Perf Week | -17.48% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 6.2M | Perf Month | -51.29% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | - | Inst Own | 10.05% | Short Float | 2.39% | Perf Quarter | -75.54% |
| Income | -0.45B | P/S | 0.38 | EPS this Y | - | Inst Trans | -2.96% | Short Ratio | 3.61 | Perf Half Y | -66.04% |
| Sales | 0.03B | P/B | - | EPS next 5Y | - | ROA | -265.83% | Short Interest | 0.15M | Perf YTD | -77.62% |
| Book/sh | -43.83 | P/C | 20.61 | EPS past 3/5Y | -81.59% -392.41% | ROE | - | 52W High | -89.89% ($16.81) | Perf Year | -85.22% |
| Cash/sh | 0.08 | P/FCF | 3.22 | Sales past 3/5Y | -7.35% - | ROIC | - | 52W Low | -6.08% ($1.81) | Perf 3Y | -95.24% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -310.88% | Gross Margin | 29.18% | Volatility(W/M) | 11.49% 9.19% | Perf 5Y | -99.23% |
| Dividend TTM | - | EV/Sales | 3.64 | Sales Y/Y TTM | -28.55% | Oper. Margin | -903.52% | ATR (14) | 0.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.06 | EPS Q/Q | -124.28% | Profit Margin | -1418.45% | RSI (14) | 13.44 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.07 | Sales Q/Q | -22.78% | SMA20 | -27.98% ($2.36) | Beta | 1.84 | Target Price | $392.26 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -55.93% ($3.86) | Rel Volume | 1.94 | Prev Close | $1.83 |
| Employees | 34 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -67.36% ($5.21) | Avg Volume(3M) | 0.04M | Price | $1.7 |
| IPO | 2021/3/5 | Option/Short | No/Yes | Trades | 219 | Volume | 79,923 | Change | -7.1% |
💊 This is a US pharmaceutical company focused on the development and commercialization of non-opioid pain therapies. Its commercialized products include ZTlido, a topical patch used for postherpetic neuralgia; ELYXYB, an oral solution for the acute treatment of migraines; and GLOPERBA, an oral colchicine for the prevention of gout, all of which expand non-opioid alternatives to narcotic painkillers.
Over the past 1 year, on the lower side
90% below its 1-year high.
Traded more than usual. That is 194% of its average volume.
SCLX has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $38. Peers typically go for $316.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.2%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 10.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #20 of 21 in the industry
Based on market cap of $12M.
AMRN#17 Amarin Corp ADR $244M PER - 
NSRX#18 Nasus Pharma Ltd $34M PER - 
MIRA#19 Mira Pharmaceuticals Inc $23M PER - SCLX#20 Scilex Holding Company $12M PER - 
MDCX#21 Medicus Pharma Ltd $3M PER - 
FAQ
What kind of company is SCLX?
SCLX belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of SCLX?
The market cap of SCLX is approximately $12M, ranking 5,355 within its sector.
What is the 52-week high and low for SCLX?
SCLX has recorded a 52-week high of $16.81 and a low of $1.81.
